“Donanemab” Significantly Slowed Cognitive and Functional Decline for
Early Alzheimer’s Disease Eli Lilly Announced May 2023
An experimental drug developed by Eli Lilly and Company “significantly slowed both cognitive and functional decline” in people with early symptomatic Alzheimer’s disease. The study enrolled more than 1,700 people with mild cognitive impairment and mild dementia, with the confirmed presence of Alzheimer’s Disease neuropathology.
The testing was based on measuring cognition and activities of daily living such as managing finances, driving, engaging in hobbies, and conversing about current events. All secondary endpoints of cognitive and functional decline were also met with statistically significant clinical benefits.
The positive results of the experimental drug Donanemab in the TRAILBLAZER-ALZ 2 Phase 3 study showed participants experienced a 39% lower risk of progressing to the next stage of disease compared with those on the placebo.
Eli Lilly plans to make a submission to the Food and Drug Administration this quarter as well as working with global regulators to achieve expedient traditional approvals.
For a fuller detailed report, go to Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Comments